- Research Methods &
- Research Training
- Research Into
|Title||Growth in the concurrent use of antipsychotics with other psychotropic medications in Medicaid-enrolled children.|
|Publication Type||Journal Article|
|Year of Publication||2014|
|Authors||Kreider AR, Matone M, Bellonci C, dosReis S, Feudtner C, Huang YS, Localio R, Rubin DM|
|Journal||J Am Acad Child Adolesc Psychiatry|
|Date Published||2014 Sep|
|Keywords||Adolescent, Antipsychotic Agents, Child, Drug Prescriptions, Female, Humans, Male, Medicaid, Polypharmacy, Psychotropic Drugs, United States|
OBJECTIVE: Second-generation antipsychotics (SGAs) have increasingly been prescribed to Medicaid-enrolled children; however, there is limited understanding of the frequency of concurrent SGA prescribing with other psychotropic medications. This study describes the epidemiology of concurrent SGA use with 4 psychotropic classes (stimulants, antidepressants, mood stabilizers, and α-agonists) among a national sample of Medicaid-enrolled children and adolescents 6 to 18 years old between 2004 and 2008.
METHOD: Repeated cross-sectional design was used, with national Medicaid Analytic eXtract data (10.6 million children annually). Logit and Poisson regression, standardized for year, demographics, and Medicaid eligibility group, estimated the probability and duration of concurrent SGA use with each medication class over time and examined concurrent SGAs in relation to clinical and demographic characteristics.
RESULTS: While SGA use overall increased by 22%, 85% of such use occurred concurrently. By 2008, the probability of concurrent SGA use ranged from 0.22 for stimulant users to 0.52 for mood stabilizer users. Concurrent SGA use occurred for long durations (69%-89% of annual medication days). Although the highest users of concurrent SGA were participants in foster care and disability Medicaid programs or those with behavioral hospitalizations, the most significant increases over time occurred among participants who were income-eligible for Medicaid (+13%), without comorbid ADHD (+15%), were not hospitalized (+13%), and did not have comorbid intellectual disability (+45%).
CONCLUSION: Concurrent SGA use with other psychotropic classes increased over time, and the duration of concurrent therapy was consistently long term. Concurrent SGA regimens will require further research to determine efficacy and potential drug-drug interactions, given a practice trend toward more complex regimens in less-impaired children/adolescents.
|Alternate Journal||J Am Acad Child Adolesc Psychiatry|
|Grant List||R01 HS01855001A1 / HS / AHRQ HHS / United States|